» Go to news main
Just published! Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- Just published! No difference in cerebral perfusion between the wild‑type and the 5XFAD mouse model of Alzheimer’s disease
- Just published! Canadian Stroke Best Practice Recommendations: Acute Stroke Management, 7th Edition Practice Guidelines Update, 2022
- Physician Leadership Workshop for Women in Radiology
- ICRE
- Just published! Intra‑individual comparison of 18F‑sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC‑A1): a multicentre, phase 3 trial
- Just published! Surgical or Endovascular Treatment of MCA Aneurysms: An Agreement Study
- Just published! Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline
- Just published! Preparedness of Residents and Medical Students for the Transition to Competence by Design in Diagnostic Radiology Post‑Graduate Medical Education
Comments
comments powered by Disqus